Background: Polcalcins are highly cross-reactive pollen panallergens. Less than 10% of allergic patients are sensitized to polcalcins. All pollen species are considered able to sensitize patients to this panallergen. Objective: We aimed to assess the presence of polcalcins in various pollen extracts used in allergen immunotherapy. Methods: ELISA inhibition experiments were performed with sera from patients sensitized to polcalcin and rPhl p 7 and rBet v 4. Recombinant polcalcin was used as the substrate and freshly prepared pollen extracts as inhibitors. Results: All pollen extracts induced significant inhibition of IgE reactivity to rBet v 4, whereas only grass pollen extract induced marked inhibition of IgE reactivity to rPhl p 7. Conclusion: Grass polcalcin probably contains more epitopes than polcalcins from other pollen sources. Grass pollen could be responsible for sensitization to polcalcins, and grass pollen immunotherapy is likely to be an option for polcalcin-hypersensitive patients.
Introduction
Polcalcins are 2 EF-hand calcium-binding proteins present in the pollen of all flowering plants, including grasses, trees, and weeds [1] [2] [3] [4] [5] [6] [7] . About 40 members of this protein family have been identified to date. Fewer than 10% of pollen-allergic patients are sensitized to these minor allergens [8] , although this percentage may vary among individuals sensitized to specific pollen sources [1, [9] [10] [11] . The high degree of sequence homology in polcalcins underlies their extensive crossreactivity [12] [13] [14] , although Phl p 7 (the grass polcalcin) seems to be the strongest IgE binder [12] . The clinical relevance of sensitization to polcalcins is unclear, as no investigations have been performed on the role of these aeroallergens using nasal or bronchial challenge tests. In a recent clinical study, a minority of patients experienced respiratory symptoms throughout the flowering period of all the pollen species analyzed, although most had symptoms limited to a specific period, generally springtime [8] . All pollen species are considered able to induce polcalcin sensitization; however, it is difficult to demonstrate which allergens a patient is sensitized to, because most reactors show primary hypersensitivity to ≥1 allergen source [15] . Allergen immunotherapy is currently the only treatment able to modify the natural history of allergic disease. In view of the high homology of polcalcins, extracts from all pollen species might theoretically be able to desensitize hypersensitive patients, although this hypothesis has not been investigated to date. The area of Milan, Italy, has features of both the Mediterranean climate and the central European climate and is characterized by the presence of significant levels of the most relevant pollens in Europe, including grass, mugwort, ragweed, pellitory, birch, hazel, plane, cypress, plantain, and Oleaceae (mainly privet and ash). It is therefore an ideal site to investigate the origin of sensitization to polcalcins. We analyzed various pollen extracts to determine their polcalcin content and assessed the immune reactivity of the polcalcins using 2 recombinant members of this allergen family.
Patients and Methods
The study was performed with sera from 9 polcalcinhypersensitive adults (3 males, 6 females), all of whom experienced cutaneous reactions to at least 4 pollen sources in skin prick tests (SPT) with commercial extracts of grass, mugwort, ragweed, pellitory, plantain, birch, plane, olive, and cypress (Allergopharma) [8] and strong IgE reactivity to Phl p 7 (grass polcalcin) in ImmunoCAP (Thermo Fisher Scientific).
Extracts of grass, birch, ragweed, pellitory, and olive pollen (Allergon) were freshly prepared using defatted pollen, which was extracted (8%) in 0.1 M phosphate-buffered saline (PBS), pH 7.4, after shaking overnight at 4°C. After centrifuging, the supernatant was harvested and dialyzed against the same buffer. Protein content, which was measured following the method of Bradford [16] , was 3.3 mg/mL, 0.8 mg/mL, 2.6 mg/mL, 2.3 mg/mL, and 1.0 mg/mL for grass, birch, ragweed, pellitory, and olive pollen extracts, respectively. All extracts were used to inhibit the reactivity of the patients' sera to recombinant grass and birch polcalcins (rPhl p 7, and rBet v 4, Thermo Fisher Scientific) in an ELISA. Briefly, rPhl p 7 or rBet v 4 was used at a concentration of 0.25 µg/100 µL of coating buffer (15 mmol/L Na 2 CO 3 , 35 mmol/L NaHCO 3 , pH 9.6) per well to coat 96-well plates (Maxisorp Nunc). After washing with 0.1 M PBS, pH 7.4, and 0.05% Tween 20 (Sigma), the wells were saturated with 2% bovine serum albumin in PBS (dilution buffer) for 2 hours at room temperature. After further washing, 100 µL of control and patient sera diluted 1:4 in PBS was added to the wells and incubated for 2 hours at room temperature. The wells were then washed again, and bound specific IgE was detected by adding peroxidase-conjugated goat antihuman IgE (diluted 1:3000, Biospacific); the colorimetric reaction was developed using tetramethyl-benzidine/H 2 O 2 as the substrate. The enzyme reaction was stopped after 20 minutes by the addition of HCl 1 mol/L, and absorbance values were read at 450 nm using a spectrophotometer. IgE levels were expressed as optical density units (OD ×1000). Based on the mean ±2SD obtained in normal controls, values <300 OD were considered negative. In inhibition studies, patients' sera were pre-absorbed overnight at 4°C with 50 µg of pollen or house dust mite extract (negative control) (Lofarma) in a final volume of 200 µL.
In order to detect the origin of polcalcin sensitization in this geographic area, we reviewed clinical and serological data from 52 consecutive polcalcin-hypersensitive patients seen at the Clinica San Carlo, Paderno Dugnano, Italy. All patients experienced cutaneous reactions to at least 4 of the following seasonal allergens: grass, mugwort, ragweed, pellitory, plantain, birch, plane, olive, and cypress. Polcalcin reactivity was demonstrated by levels of IgE to Phl p 7 >1 kU A /L (ImmunoCAP, Thermo Fisher Scientific) and, in 23 cases, also by strong skin reactivity during SPT with a date palm polcalcin [8] . 
Results
The results of the ELISA inhibition experiments using recombinant Phl p 7 and Bet v 4 as substrates are shown in Table 1 . The absorption of the serum pool with all pollen extracts resulted in significant inhibition of IgE reactivity to rBet v 4. In contrast, only grass pollen extract induced marked inhibition of IgE reactivity to rPhl p 7 (87%), whereas the inhibition induced by pre-absorption with all the other extracts did not exceed 33%. A house dust mite extract used as a control did not induce inhibition.
The findings for the 52 polcalcin reactors are shown in Table 2 . Component-resolved diagnosis showed that most patients were sensitized to >1 allergen source. Grass pollen hypersensitivity was detected in 51 cases (98%), followed by hypersensitivity to ragweed (79%) and birch pollen (62%). Genuine olive, cypress, ragweed, and pellitory sensitization was detected in ≤38% of patients. Only 6 patients (12%) were sensitized to a single pollen source (grass in 5 cases, ragweed in 1 case).
epitopes than homologous allergens from all other pollen sources; alternatively, the results could indicate a polcalcin isoform that does not show the whole repertoire of allergenic epitopes of the natural counterpart. This would explain why all of the extracts were able to neutralize most IgE reactivity to rBet v 4 and why all of the extracts except grass were not able to neutralize IgE reactivity to rPhl p 7, which was abolished by grass pollen extract. Unfortunately, this interpretation lacks further support, since no polcalcins other than rPhl p 7 and rBet v 4 are currently on the market. Our findings suggest that grass pollen could be responsible for sensitization to polcalcin, at least in this geographic area. In fact, although most polcalcin reactors were primarily sensitized to several pollen sources (up to 6 in some cases), grass sensitization was detected in all patients except one, who was monosensitized to ragweed. These observations are in keeping with clinical data from our group showing that most polcalcin reactors have symptoms mainly in spring (8) and confirm previous findings by Tinghino et al [14] showing that Phl p 7 is the strongest IgE-binding polcalcin. Variations in polcalcin content between pollens, along with the burden of each pollen in this geographic area, might explain how patients become sensitized to polcalcins, as was previously shown for profilin [17] . Furthermore, previous studies found that sensitization to polcalcins correlates both with a higher number of primary pollen sensitizations and with disease duration [18] . The current results seem to support these findings, again suggesting the high complexity of polcalcin sensitization.
Although demonstration of IgE reactivity to polcalcins was based on the detection of IgE to Phl p 7, we do not believe that the study population was affected by a relevant selection bias, as all patients experienced skin reactions to various pollen extracts, and, in 23 cases, the patients reacted to polcalcin from date palm pollen, which is not present in this area. Thus, grass pollen polcalcin seems to contain specific epitopes that react to IgE from sensitized individuals (at least those living in this geographic area) and that are missing in homologous allergens from other sources. Another possible explanation for our results might be that although we were able to investigate only 2 recombinant proteins, natural polcalcins have several
Discussion
The aim of the present study was to confirm the presence of polcalcins in freshly prepared extracts of pollen from various sources for possible use in allergen immunotherapy for allergic patients. To this end, inhibition experiments were performed with sera from polcalcin reactors and recombinant polcalcins from 2 sources (Phl p 7 from grass and rBet v 4 from birch). To our surprise, the 2 recombinant polcalcins showed marked differences in IgE reactivity: while all pollen extracts were able to significantly inhibit IgE reactivity to rBet v 4, only grass pollen extract was able to markedly inhibit rPhl p 7. We cannot rule out the possibility that the use of a pool of sera rather than individual sera from allergic patients may have influenced the results, as IgE reactivity to polcalcins can vary between patients. In effect, using serum from a single patient, the level of inhibition induced by birch extract increased from 23% to 50% (Table 1) . Furthermore, as we did not measure polcalcin content in the pollen extracts used to perform the experiments, the results might simply reflect differences in levels of polcalcin in the extracts. Nonetheless, since the experiments were carried out using identical concentrations of both sera and rBet v 4 and rPhl p 7, another possible interpretation of our findings is that grass pollen polcalcin contains more isoforms; therefore, we cannot rule out the possibility that the available isoforms do not contain the whole repertoire of allergenic epitopes present in their natural counterpart. On the basis of these observations, we can conclude that grass pollen immunotherapy is probably the treatment of choice in severely polcalcin-sensitized patients living in this geographic area. The choice of a grass extract to treat these patients might depend not only on the primary sensitization source, but also on the content of polcalcin in grass formulas currently used for immunotherapy. However, this aspect should be investigated by checking the kinetics of specific IgG4 to Phl p 7 during immunotherapy.
